These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Primary hyperlipoproteinemia in its clinical and laboratory aspects. IV. Blood coagulation and fibrinolysis indicators]. Borodin M; Jurek D; Gregorczyk J; Pieczul-Mróz J; Cwajda H Przegl Lek; 1983; 40(10):727-32. PubMed ID: 6665208 [No Abstract] [Full Text] [Related]
3. Activation of coagulation but normal fibrinolysis in patients with type IIA hyperlipoproteinemia. Avellone G; Di Garbo V; Cordova R; Abruzzese G; Rotolo G; De Simone R; Raneli G; Bompiani G Thromb Res; 1996 Jan; 81(2):277-82. PubMed ID: 8822143 [No Abstract] [Full Text] [Related]
4. Problems of long-term treatment in children with familial hypercholesterolaemia. West RJ Prog Clin Biol Res; 1985; 188():209-11. PubMed ID: 4059258 [No Abstract] [Full Text] [Related]
6. After the failure of ENHANCEd cholesterol lowering in familial hypercholesterolemia, SEAS of problems with ezetimibe. Mascitelli L; Ravnskov U; Pezzetta F; Goldstein MR Angiology; 2009; 60(1):127-8; author reply 129-30. PubMed ID: 19049996 [No Abstract] [Full Text] [Related]
7. Effects of cod liver oil on platelets and coagulation in familial hypercholesterolemia (type IIa). Brox JH; Killie JE; Osterud B; Holme S; Nordøy A Acta Med Scand; 1983; 213(2):137-44. PubMed ID: 6340424 [TBL] [Abstract][Full Text] [Related]
8. [Effect of the combined administration of guar-bezafibrate on lipid, apolipoprotein and lipoprotein in patients with primary hyperlipoproteinemia type II]. Wirth A; Schlierf G; Middelhoff G; Arntz HR; Hansen W; Vollmar J; Bräuning C Beitr Infusionther Klin Ernahr; 1983; 12():99-108. PubMed ID: 6316922 [No Abstract] [Full Text] [Related]
9. Influence of a hypolipemic drug (procetofene) on platelet functions and lipid composition in type II B hyperlipoproteinemia. Renaud S; Morazain R; Sauvanet JP; Dumont E; Drouin P Haemostasis; 1979; 8(2):82-95. PubMed ID: 499929 [TBL] [Abstract][Full Text] [Related]
10. [Blood coagulation and fibrinolysis systems in primary hyperlipoproteinemias]. Berent H; Uchman B Pol Arch Med Wewn; 1983 Sep; 70(3):131-4. PubMed ID: 6657492 [No Abstract] [Full Text] [Related]
11. [Homozygous familial hypercholesterolemia. First case in Spain treated with lomitapide, an inhibitor of the synthesis of lipoproteins with apolipoprotein B]. Alonso R; Mata P; Alonso Y Gregorio M; de Andrés R Med Clin (Barc); 2015 Sep; 145(5):229-30. PubMed ID: 25543225 [No Abstract] [Full Text] [Related]
12. Effects of low-density lipoprotein apheresis (dextran sulphate adsorption method) on bleeding tendency in treatment patients. Florén CH; Berntorp E; Hagstam KE J Intern Med; 1995 Dec; 238(6):559-61. PubMed ID: 9422042 [No Abstract] [Full Text] [Related]
13. Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia. Vacek JL; Dittmeier G; Chiarelli T; White J; Bell HH Am J Cardiol; 1995 Jul; 76(3):182-4. PubMed ID: 7611158 [TBL] [Abstract][Full Text] [Related]
14. The prediction of the therapeutic response to cholesterol lowering drugs in an 11-year-old boy with homozygous familial hypercholesterolaemia. Bakker HD; Bruin T; Schaap MC; Lansberg PJ; Kastelein JJ J Inherit Metab Dis; 1991; 14(3):389-92. PubMed ID: 1663193 [No Abstract] [Full Text] [Related]
15. Loss of dental enamel in a patient taking cholestyramine. Curtis DM; Driscoll DJ; Goldman DH; Weidman WH Mayo Clin Proc; 1991 Nov; 66(11):1131. PubMed ID: 1943246 [TBL] [Abstract][Full Text] [Related]
16. [Behavior of serum lipids, blood coagulation factors, platelet aggregation, complement and serum immunoglobulins in a group of arteriosclerotic, hyperlipemic subjects treated with 3GS]. D'Eredità F; Avellone G; Novo S; Davì G; Abruzzese G; Di Liberti M; Pinto A; Riolo F Clin Ter; 1981 Feb; 96(3):303-24. PubMed ID: 7307448 [No Abstract] [Full Text] [Related]
17. The effects of mevinolin and neomycin alone and in combination on plasma lipid and lipoprotein concentrations in type II hyperlipoproteinemia. Hoeg JM; Maher MB; Bailey KR; Brewer HB Atherosclerosis; 1986 Jun; 60(3):209-14. PubMed ID: 3524586 [TBL] [Abstract][Full Text] [Related]
18. [Blood levels and effectiveness of beta-pyridyl carbinol in a new controlled release form in subjects with healthy metabolism and in patients with hyperlipoproteinemia II]. Schulz E; Schräpler P Ther Umsch; 1980 Feb; 37(2):137-43. PubMed ID: 7385082 [No Abstract] [Full Text] [Related]
19. [Results of 6 months, therapy of familial hypercholesterolemia (hyperlipoproteinemia type II) with colestipol]. Kuŝić M; Gavrilović M; Mihajloviĉ M; Boŝković B Srp Arh Celok Lek; 1980 Sep; 108(9):875-81. PubMed ID: 7302695 [No Abstract] [Full Text] [Related]
20. Continued benefit of lovastatin in the treatment of hypercholesterolemia in 36 patients. Wallace MB; Warren SG; Bates MC; Robinson PA W V Med J; 1995 Feb; 91(2):50-3. PubMed ID: 7610642 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]